Scientific Analysis of Biotechnology Companies

Technical evaluation of therapeutic programs and drug discovery platforms

We examine biotechnology companies by analyzing clinical programs, scientific literature, and technical documents. Our analysis focuses on therapeutic development programs and platform technologies, with particular attention to neuroscience and computational approaches to drug discovery.

Recent Analysis

View all

Introducing the Drug Exclusivity Dashboard

October 19, 2024

Drug exclusivity is an important metric to track when monitoring pharma portfolios. RxDataLab has created a dashboard to monitor estimated drug patent and exclusivity expiration in the US.

A Surge in Investigational New Drug Activity

October 7, 2024

Visualizing the rise in Investigational New Drug (IND) receipts and active INDs during 2019-2020. With no major regulatory changes, the spike appears linked to the COVID-19 pandemic, raising questions about how it shaped drug development.

Newsletter

Subscribe for updates on biotechnology research and analysis.